CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 101 enrolled
Drug / intervention
Drug: Carfilzomib + Dexamethasone +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03934684
NCT03934684Phase 4Completed
CompareCT.gov

Post-marketing Phase 4 Study to Evaluate Safety, Tolerability, and Efficacy of Kyprolis® (Carfilzomib) in Indian Patients With Relapsed or Refractory Multiple Myeloma: A Prospective, Open-label, Non-comparative, Multicenter Study

Amgen·interventional·Posted May 2, 2019·Updated May 11, 2026

In Brief

A Phase 4 clinical trial evaluating Drug: Carfilzomib + Dexamethasone and Drug: Carfilzomib + Lenalidomide + Dexamethasone for Relapsed Refractory Multiple Myeloma. Completed, enrolled 101 participants across 17 sites.

Detailed Summary

To characterize safety associated with the use of Kyprolis under the locally approved label.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRelapsed Refractory Multiple Myeloma
CountriesIndia
Collaborators--

Timeline

Phase 4CompletedFinished
2020202120222023202420252026
First PostedMay 2, 2019
Enrollment StartSep 16, 2019
Primary CompletionMar 23, 2023
Study CompletionJun 27, 2025
TodayJul 2, 2026
Enrollment to primary: 3.5 yearsPosted 7.2 years ago

Interventions

Drug: Carfilzomib + Dexamethasonedrug

Drug: Carfilzomib + Dexamethasone * Carfilzomib will be administered as a 30-minute infusion. * Dexamethasone will be taken by mouth or intravenously.

Drug: Carfilzomib + Lenalidomide + Dexamethasonedrug

Drug: Carfilzomib + Lenalidomide + Dexamethasone * Carfilzomib will be administered as a 10 minute infusion. * Lenalidomide will be taken orally. * Dexamethasone will be taken by mouth or intravenously.